Myriad Genetics Inc: (NASD: MYGN)

$34.10

0.99 (2.99%)

Volume 2,572,065

May 14 04:00 PM ET

Zacks Rank: 2-Buy

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.27%
#2	Buy	18.43%
#3	Hold	9.86%
#4	Sell	4.09%
#5	Strong Sell	1.87%
S&P	500	9.59%

Overview Quote

            Stock Activity
        
		Day Low - High
		33.37 - 34.70
	
		52wk Low - High
		22.02 - 34.70
	
		Previous Close
		33.11
	
		Avg. Volume
		1,183,491
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		2.67 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.32
	
		PE (Forward)
		19.89
	
		Current Year Est.
		1.66
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.27%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.43%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        9.86%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.09%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        1.87%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.59%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		2
Buy

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		79 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/10/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            19.89
                        
                            PEG Ratio
                            1.58
                        
                            Current Year Est.
                            1.66
                        
                            Current Quarter Estimate
                            0.43
                        
                            Most Accurate Estimate
                            0.43
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-13-2013
                        
                            EPS Last Year
                            1.58
                        
                            Expected Earnings Growth
                            12.62%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Myriad Genetics, Inc. uses gene-based medicine to develop therapeutic and molecular diagnostic products.  They employ a variety of proprietary proteomic technologies to discover disease genes and to understand the role these genes and their related proteins play in the onset and progression of disease. They have integrated these technologies using bioinformatics and robotics systems to conduct their research efforts on a high-throughput basis. This has enabled them to identify numerous proteins as targets for new drugs and molecular diagnostic tests.   
Full MYGN Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
MYGN Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (06/2013)	Next Year (06/2014)
Average Estimate	0.43	0.43	1.66	1.86
Number of Estimates	9	4	8	8
Low Estimate	0.40	0.37	1.65	1.60
High Estimate	0.45	0.45	1.68	NA
Year Ago EPS	0.34	0.36	1.30	1.66
EPS Growth	25.82%	18.75%	28.08%	11.71%

More MYGN Estimates

Average Earnings Estimates for MYGN

EPS Growth for MYGN

Industry Analysis

Name	Symbol	Previous Close
MYRIAD GENETICS	MYGN	33.11
AETERNA ZENTARS	AEZS	1.87
ANIKA THERAPEUT	ANIK	13.90
GENTIUM SPA-ADR	GENT	8.31
NOVELOS THERAPT	NVLT	0.44
AASTROM BIOSCI	ASTM	0.60
ACHILLION PHARM	ACHN	7.25
AFFYMAX INC	AFFY	1.31
ALEXION PHARMA	ALXN	104.86
ALKERMES INC	ALKS	31.47

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Genomic Gains Coverage for DCIS

May 13, 2013

GHDX Reports Loss, Beats on Revs

May 13, 2013

Earnings Beat for PETS, Margins Up

May 13, 2013

MYGN Earnings Easily Beat, Guidance Up

May 08, 2013

Qiagen Misses Earnings, Guides Low

May 01, 2013

Myriad Downgraded to Neutral

Apr 18, 2013

Myriad's New Alliance for HRD Test

Mar 28, 2013

Myriad Retained at Outperform

Mar 08, 2013

More MYGN Zacks Commentary

Financials

EPS TTM	1.58
Sales	496
Net Income	132
Price/Earnings	20.96
Price/Book	4.01
Price/Cash Flow	23.18
Price/Sales	4.66

More MYGN Financials

News

Buyers Accumulate Shares of Myriad Genetics, Up 3.4% - Financial News Network Online - Market Movers

May 14, 2013

Myriad Genetics (MYGN) Showing Bullish Technicals But Could Break Through $34.11 Resistance - Freshbrewedmedia

May 14, 2013

Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference - Globenewswire

May 14, 2013

Stocks Add To Gains; LinkedIn Retakes 50-Day Line - Investors Business Daily

May 14, 2013

Volume Spike Detected in Shares of Myriad Genetics as They Move Higher on 1.5x Above-Average Volume (MYGN) - Financial News Network Online - Unusual Volume

May 14, 2013

Watch for Continued Gains in Shares of Myriad Genetics (MYGN) - Financial News Netwfork Online - 52-Week High-Lows

May 13, 2013

CSU-Led Study Assesses Impact of Pending Landmark U.S. Supreme Court Case on Gene Patents - M2

May 10, 2013

Position Yourself for Big Returns in the Stem Cell Space: Jason Kolbert - Kapitall

May 10, 2013

See All News Stories on MYGN

Broker Recommendations

Current ABR	2.18
ABR (Last Week)	2.18
# of recs in ABR	11
Average Target Price	32.67
Industry Rank by ABR	79 out of 265
Rank in Industry	5 out of 155

More MYGN Broker Recommendations

Day Low - High	33.37 - 34.70
52wk Low - High	22.02 - 34.70
Previous Close	33.11
Avg. Volume	1,183,491
Industry	MED-BIOMED/GENE
Market Cap	2.67 B
Div - Yield	0.00 - 0.00
Beta	0.32
PE (Forward)	19.89
Current Year Est.	1.66
Quarterly Earnings ESP	0.00%

PE (Forward)	19.89
PEG Ratio	1.58
Current Year Est.	1.66
Current Quarter Estimate	0.43
Most Accurate Estimate	0.43
Earnings ESP	0.00%
Next Earnings Report Date	08-13-2013
EPS Last Year	1.58
Expected Earnings Growth	12.62%

Username: Password:

Remember me [?]

Myriad Genetics Inc: (NASD: MYGN)

$34.10

0.99 (2.99%)

Volume 2,572,065

May 14 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

Financials

News

Broker Recommendations